Related Experiment Video
Updated: May 9, 2025

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
Published on: May 11, 2021
G protein-coupled receptor GPR182 negatively regulates sprouting angiogenesis via modulating CXCL12-CXCR4 axis
Changsheng Chen1, Wei Liu2,3,4, Fang Yuan5,6
1School of Life Sciences, Nantong Laboratory of Development and Diseases, Nantong University, Seyuan Road 9, Nantong, Jiangsu Province, 226019, China. c.chen@ntu.edu.cn.
Abstract:
Angiogenesis is a critical process for tumor progression, regulated by various signaling pathways. Although antiangiogenic therapies targeting the VEGF pathway have shown potential, their effectiveness is inconsistent across different tumor types. GPR182, an endothelial cell-specific G protein-coupled receptor, is frequently downregulated in hypervascular tumors, but its specific role in angiogenesis has not been well defined. Our study reveals that GPR182 expression is markedly reduced in hepatocellular carcinoma (HCC) and inversely correlates with CD31, a pan-endothelial marker. In zebrafish embryos, Gpr182 deficiency resulted in enhanced angiogenic sprouting and hypervascularization, and GPR182-deficient human umbilical vein endothelial cells (HUVECs) showed increased migration and proliferation. At the molecular level, GPR182 acts as a decoy receptor, binding CXCL12 and regulating its gradient, which in turn suppresses CXCR4-mediated angiogenesis. The pharmacological blockade of CXCR4 with AMD3100 corrected the abnormal angiogenic phenotype in Gpr182-deficient zebrafish embryos and in the livers of a zebrafish HCC model. This work uncovers GPR182 as a negative regulator of angiogenesis, a key process in tumor growth and metastasis, and proposes that targeting GPR182 may offer a novel therapeutic approach for antiangiogenic strategies in cancer treatment.
Insights
GPR182 negatively regulates tumor angiogenesis by binding CXCL12. Its deficiency promotes tumor growth, suggesting GPR182 as a potential therapeutic target for novel antiangiogenic cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Vascular Biology
Background:
- Angiogenesis is crucial for tumor progression, but antiangiogenic therapies show variable efficacy.
- GPR182, an endothelial cell receptor, is downregulated in tumors, yet its role in angiogenesis is unclear.
- Hepatocellular carcinoma (HCC) frequently exhibits reduced GPR182 and increased vascularity.
Purpose of the Study:
- To define the role of GPR182 in angiogenesis and tumor progression.
- To investigate the molecular mechanisms underlying GPR182-mediated angiogenesis regulation.
- To explore GPR182 as a potential therapeutic target for cancer treatment.
Main Methods:
- Assessed GPR182 expression in HCC and correlated with CD31.
- Utilized zebrafish models (embryos and HCC) to study Gpr182 deficiency effects on angiogenesis.
- Examined GPR182-deficient human umbilical vein endothelial cell (HUVEC) behavior.
- Investigated the molecular interaction of GPR182 with CXCL12 and CXCR4 signaling.
- Tested the efficacy of CXCR4 blockade (AMD3100) in correcting angiogenic defects.
Main Results:
- GPR182 expression inversely correlated with CD31 in HCC.
- Gpr182 deficiency in zebrafish led to enhanced angiogenesis and hypervascularization.
- GPR182-deficient HUVECs exhibited increased migration and proliferation.
- GPR182 functions as a decoy receptor for CXCL12, suppressing CXCR4-mediated angiogenesis.
- AMD3100 treatment reversed abnormal angiogenesis in Gpr182-deficient models.
Conclusions:
- GPR182 is a novel negative regulator of angiogenesis.
- GPR182 deficiency promotes tumor vascularization and growth.
- Targeting GPR182 or its downstream pathways offers a potential new antiangiogenic strategy for cancer therapy.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
TGF - β Signaling Pathway
Hedgehog Signaling Pathway
Mechanism of Angiogenesis
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:

